[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI2628798T1 - Profilaktično ali terapevtsko sredstvo za fibrozo - Google Patents

Profilaktično ali terapevtsko sredstvo za fibrozo

Info

Publication number
SI2628798T1
SI2628798T1 SI201131728T SI201131728T SI2628798T1 SI 2628798 T1 SI2628798 T1 SI 2628798T1 SI 201131728 T SI201131728 T SI 201131728T SI 201131728 T SI201131728 T SI 201131728T SI 2628798 T1 SI2628798 T1 SI 2628798T1
Authority
SI
Slovenia
Prior art keywords
fibrosis
prophylactic
therapeutic agent
therapeutic
agent
Prior art date
Application number
SI201131728T
Other languages
English (en)
Inventor
Esteban C. Gabazza
Tetsu Kobayashi
Hidekazu Toyobuku
Ayako Fukuda
Tetsuya Hasegawa
Original Assignee
Mie University
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mie University, Otsuka Pharmaceutical Co., Ltd. filed Critical Mie University
Publication of SI2628798T1 publication Critical patent/SI2628798T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SI201131728T 2010-10-14 2011-10-14 Profilaktično ali terapevtsko sredstvo za fibrozo SI2628798T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010231946 2010-10-14
EP11832611.5A EP2628798B1 (en) 2010-10-14 2011-10-14 Prophylactic or therapeutic agent for fibrosis
PCT/JP2011/073628 WO2012050181A1 (ja) 2010-10-14 2011-10-14 線維症予防又は治療剤

Publications (1)

Publication Number Publication Date
SI2628798T1 true SI2628798T1 (sl) 2019-06-28

Family

ID=45938402

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131728T SI2628798T1 (sl) 2010-10-14 2011-10-14 Profilaktično ali terapevtsko sredstvo za fibrozo

Country Status (30)

Country Link
US (6) US8772262B2 (sl)
EP (2) EP3517614A1 (sl)
JP (4) JP6022940B2 (sl)
KR (2) KR101853799B1 (sl)
CN (2) CN106086022B (sl)
AR (1) AR083445A1 (sl)
AU (1) AU2011314653B2 (sl)
BR (1) BR112013006541A2 (sl)
CA (1) CA2813163C (sl)
CO (1) CO6660456A2 (sl)
CY (1) CY1121945T1 (sl)
DK (1) DK2628798T3 (sl)
ES (1) ES2720135T3 (sl)
HK (1) HK1184189A1 (sl)
HR (1) HRP20190722T1 (sl)
HU (1) HUE043891T2 (sl)
IL (2) IL224791A (sl)
LT (1) LT2628798T (sl)
MX (1) MX348555B (sl)
MY (1) MY165964A (sl)
NZ (2) NZ630501A (sl)
PL (1) PL2628798T3 (sl)
PT (1) PT2628798T (sl)
RU (1) RU2583290C2 (sl)
SG (3) SG10201907649QA (sl)
SI (1) SI2628798T1 (sl)
TR (1) TR201905060T4 (sl)
TW (2) TWI679023B (sl)
WO (1) WO2012050181A1 (sl)
ZA (1) ZA201301279B (sl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
WO2015093495A1 (ja) * 2013-12-16 2015-06-25 株式会社ボナック TGF-β1遺伝子発現制御のための一本鎖核酸分子
US10337009B2 (en) 2014-12-15 2019-07-02 Bonac Corporation Single-stranded nucleic acid molecule for inhibiting TGF-β1 expression
WO2017043490A1 (ja) * 2015-09-07 2017-03-16 協和発酵バイオ株式会社 自然免疫誘導効果が増強した二重鎖リボ核酸
EP3369816B1 (en) * 2015-10-30 2024-03-13 Toray Industries, Inc. Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-beta1 gene

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
WO2003035869A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
WO2003035083A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
US20040121348A1 (en) 2001-10-26 2004-06-24 Ribopharma Ag Compositions and methods for treating pancreatic cancer
US20040248835A1 (en) 2001-10-26 2004-12-09 Anja Krebs Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus
ATE536408T1 (de) 2003-04-02 2011-12-15 Dharmacon Inc Modifizierte polynukleotide zur verwendung bei rna-interferenz
US7668257B2 (en) * 2003-10-01 2010-02-23 Samsung Electronics Co., Ltd. Transmissions with reduced code rate in 8VSB digital television
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
JP2007119396A (ja) 2005-10-28 2007-05-17 Hosokawa Funtai Gijutsu Kenkyusho:Kk 核酸化合物封入ナノ粒子を含む経肺投与用医薬製剤
EP1951263A4 (en) 2005-11-21 2009-11-18 Johnson & Johnson Res Pty Ltd MULTITARGETING DISTURBING RNAS WITH TWO ACTIVE STRANDS AND DESIGN AND APPLICATION METHODS
JP2009522303A (ja) * 2005-12-30 2009-06-11 ウェイ−ウー ヒー, 瘢痕を生じない皮膚創傷治癒を促進するsiRNA組成物および創傷処置の方法
US7846908B2 (en) 2006-03-16 2010-12-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of TGF-beta and therapeutic uses thereof
US20080293136A1 (en) 2007-03-02 2008-11-27 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting akt gene expression and uses thereof
US20100047909A1 (en) 2007-03-02 2010-02-25 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof
US20080287383A1 (en) 2007-03-02 2008-11-20 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
US20080286866A1 (en) 2007-03-02 2008-11-20 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting vegf gene expression and uses thereof
US20100112687A1 (en) 2007-03-02 2010-05-06 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
CA2679244A1 (en) 2007-03-02 2009-03-05 Mdrna, Inc. Nucleic acid compounds for inhibiting myc gene expression and uses thereof
WO2008109518A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
WO2008109357A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting apob gene expression and uses thereof
JP2010519912A (ja) 2007-03-02 2010-06-10 エムディーアールエヌエー,インコーポレイテッド Ras遺伝子の発現を抑制するための核酸化合物およびその使用
EP2126082A1 (en) 2007-03-02 2009-12-02 MDRNA, Inc. Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof
JP2010519908A (ja) 2007-03-02 2010-06-10 エムディーアールエヌエー,インコーポレイテッド Hif1a遺伝子の発現を抑制するための核酸化合物およびその使用
US20100105134A1 (en) 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2008109548A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tgfb gene expression and uses thereof
AU2008247488B2 (en) 2007-05-04 2014-02-27 Marina Biotech, Inc. Amino acid lipids and uses thereof
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 1本鎖環状rnaおよびその製造方法
USRE46873E1 (en) * 2007-11-06 2018-05-29 Sirnaomics, Inc. Multi-targeted RNAi therapeutics for scarless wound healing of skin
UA97559C2 (uk) 2007-11-08 2012-02-27 Оцука Фармасьютікал Ко., Лтд. Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти
JP5697988B2 (ja) * 2007-12-27 2015-04-08 プロチバ バイオセラピューティクス インコーポレイティッド 干渉rnaを使用したポロ様キナーゼ発現のサイレンシング方法
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
KR20100131509A (ko) 2008-03-31 2010-12-15 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 Rna 간섭 효과가 높은 2본쇄 지질 수식 rna
KR102453078B1 (ko) 2010-03-24 2022-10-11 피오 파마슈티칼스 코프. 진피 및 섬유증성 적응증에서의 rna 간섭
CN103200945B (zh) * 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS

Also Published As

Publication number Publication date
HK1184189A1 (zh) 2014-01-17
MX2013003698A (es) 2013-05-20
CN103119166A (zh) 2013-05-22
AU2011314653B2 (en) 2015-09-03
PT2628798T (pt) 2019-05-14
US9637743B2 (en) 2017-05-02
AR083445A1 (es) 2013-02-27
KR102167225B1 (ko) 2020-10-20
SG10201907649QA (en) 2019-09-27
WO2012050181A1 (ja) 2012-04-19
ES2720135T3 (es) 2019-07-18
TWI679023B (zh) 2019-12-11
IL224791A (en) 2017-09-28
SG189245A1 (en) 2013-05-31
IL245995A0 (en) 2016-07-31
US20190010500A1 (en) 2019-01-10
MX348555B (es) 2017-06-16
TWI572715B (zh) 2017-03-01
EP2628798A1 (en) 2013-08-21
RU2583290C2 (ru) 2016-05-10
BR112013006541A2 (pt) 2017-09-19
HRP20190722T1 (hr) 2019-06-14
IL245995B (en) 2018-05-31
CN103119166B (zh) 2016-06-22
JPWO2012050181A1 (ja) 2014-02-24
US20160130586A1 (en) 2016-05-12
NZ630501A (en) 2015-11-27
EP2628798A4 (en) 2014-02-26
CO6660456A2 (es) 2013-04-30
TR201905060T4 (tr) 2019-05-21
SG10201508365RA (en) 2015-11-27
KR20180049152A (ko) 2018-05-10
MY165964A (en) 2018-05-18
US20130217754A1 (en) 2013-08-22
JP2018088923A (ja) 2018-06-14
US8772262B2 (en) 2014-07-08
EP2628798B1 (en) 2019-03-27
US20200291406A1 (en) 2020-09-17
ZA201301279B (en) 2014-04-30
US9273314B2 (en) 2016-03-01
EP3517614A1 (en) 2019-07-31
HUE043891T2 (hu) 2019-09-30
KR20140020820A (ko) 2014-02-19
CN106086022B (zh) 2020-10-09
NZ609440A (en) 2014-10-31
CA2813163C (en) 2020-11-03
TW201216988A (en) 2012-05-01
TW201627012A (zh) 2016-08-01
AU2011314653A1 (en) 2013-03-28
PL2628798T3 (pl) 2019-09-30
JP2017000155A (ja) 2017-01-05
JP6022940B2 (ja) 2016-11-09
CN106086022A (zh) 2016-11-09
US20170198293A1 (en) 2017-07-13
US20140288151A1 (en) 2014-09-25
CY1121945T1 (el) 2020-10-14
US10125366B2 (en) 2018-11-13
LT2628798T (lt) 2019-05-10
DK2628798T3 (da) 2019-05-06
KR101853799B1 (ko) 2018-05-02
RU2013121802A (ru) 2014-11-20
JP2020078314A (ja) 2020-05-28
CA2813163A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
HRP20181615T1 (hr) Terapijsko sredstvo koje izaziva citotoksičnost
EP2552323A4 (en) COMBINATION THERAPY
EP2671585A4 (en) THERAPEUTIC OR PROPHYLACTIC AGGREGATE AGAINST CACHEXIA
PL2554541T3 (pl) Środek terapeutyczny lub środek profilaktyczny na fibromialgię
PL2529739T3 (pl) Środek terapeutyczny lub profilaktyczny na choroby dróg żółciowych
IL245995B (en) Prophylactic or medical agent for fibrosis
HK1173368A1 (en) Pigmentation-preventing or-ameliorating agent
ZA201300704B (en) Foaming cleanser
EP2745838A4 (en) PROPHYLACTIC AGENT AND / OR THERAPEUTIC AGENT FOR SEPTICEMIA
EP2604607A4 (en) AGENT FOR THE PREVENTION AND TREATMENT OF NON-ALCOHOLIC STÉATOHÉPATITE
GB0900484D0 (en) Therapeutic agent
IL224340A (en) Sanitary cause
PL2599487T3 (pl) Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu
EP2594275A4 (en) AGENT FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF DIABETES
EP2647386A4 (en) Lissencephaly THERAPEUTIC
EP2436385A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST LUNG FIBROSIS
HK1186457A1 (en) Halogenated diethyltoluenediamines
EP2640832A4 (en) NEW ETHIOLOGICAL AGENT
GB201003727D0 (en) Therapeutic agent
GB201010582D0 (en) Therapeutic agents
GB201010577D0 (en) Therapeutic agents
GB201014963D0 (en) Therapeutic agents
GB201012102D0 (en) Therapeutic agents
GB201012100D0 (en) Therapeutic agents
GB201010583D0 (en) Therapeutic agents